University of Minnesota Grants Calyxt an Exclusive License to its Homologous Recombination Technology in Plants
July 28, 2015 —New Brighton (Minnesota, USA) — Calyxt, Inc., a Minnesota-based company focusing on developing healthier food products, today announced that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide rights to use the technology covered by the patent rights of the family PCT/US2013/046495 entitled “Gene Targeting Using Replicating DNA Molecules”. In combination with nuclease technologies, this delivery method, which is based on a group of DNA viruses known as geminiviruses, enables efficient targeted modification of plant genomes and was developed by Professor Dan Voytas’ laboratory in the University of Minnesota.
Homologous recombination is a central cellular process involved in many aspects of genome maintenance such as DNA repair, replication, telomere maintenance, and meiotic chromosomal segregation. The targeted editing of plant genomes by homologous recombination is key to create a number of valuable traits.
“We are excited to add this innovation to our broad technology portfolio, that will reinforce our leading position in the field of plant gene editing, while helping expand our pipeline of healthier food products that meet consumer needs,” said Luc Mathis, Chief Executive Officer of Calyxt, Inc.